Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer
Trial Parameters
Brief Summary
This study evaluates whether adaptive stereotactic body radiotherapy (SBRT) provides dosimetric advantages compared to non-adaptive SBRT in localized prostate cancer. Five low-dose CT scans are performed before each SBRT session to assess anatomical variations (bladder filling, rectal volume) and determine if a dosimetric recalculation would have been required. The study also evaluates cumulative dose to organs at risk, patient-reported quality of life over 24 months, and overall and recurrence-free survival.
Eligibility Criteria
Inclusion Criteria: * Male aged ≥60 years * Localized prostate cancer of low or intermediate risk (T1-T2) * Gleason score 6-7 * PSA \<15 ng/mL * No evidence of metastatic disease * Radiotherapy indicated for prostate cancer * Affiliated with or benefiting from a French social security system * French-speaking patient * Patient appropriately informed and having signed a written informed consent form Exclusion Criteria: * Unable to read, write, or understand French * Vulnerable patient as defined by Article L1121-6 of the French Public Health Code * Adult under guardianship, curatorship, or legal protection ("sauvegarde de justice") * Patient unable to personally provide informed consent according to Article L1121-8 of the French Public Health Code * Patient already included in another interventional study that could interfere with study outcomes * History of urological (prostate) or digestive surgery that could influence study outcomes * Refusal to sign the written informed consent form